Table 2.

Eight-week disease control status by treatment and marker groups

Number of patients with disease control / total number of patients (%)
 Treatment 
Marker groupErlotinibVandetanibErlotinib + bexaroteneSorafenibTotal
EGFR6/17 (35%) 11/27 (41%)a 11/20 (55%)a9/23 (39%)37/87 (43%)
KRAS/BRAF1/7 (14%)0/3 (0%)1/3 (33%)  11/14 (79%)a13/27 (48%)
VEGF/VEGFR-2 10/25 (40%)a6/16 (38%)0/3 (0%)  25/39 (64%)a41/83 (49%)
RXR/Cyclin D10/1 (0%)0/0 (NA)  1/1 (100%)a1/4 (25%)2/6 (33%)
None3/8 (38%)0/6 (0%)  5/9 (56%)a  11/18 (61%)a19/41 (46%)
Total20/58 (34%)17/52 (33%)18/36 (50%)57/98 (58%)112/244 (46%)
  • a Cells showing effective treatments within specific marker groups defined as the probability of DCR given data is 80% or greater. Only 1 patient in the RXR/CycD1 marker group received erlotinib + bexarotene.